Meet Josh Fox
Contact Josh:
1.617.239.8350
JDFox@mintz.com
Full Bio on Mintz.com
Fun facts:
I am a proud uncle and diehard Red Sox fan, enjoy running 5Ks, and love music – concerts, theater, and playing piano when I can.
If I weren’t a lawyer, I would be …
helping to run a charity, foundation, or nonprofit.
My favorite app is …
MLB At Bat. For about six months of the year, I “need” regular access to Red Sox scores.
Companies I’ve helped to grow and thrive:
Aquinnah Pharmaceuticals
Asimov
Axoft
Bilayer Therapeutics
Droplette
Hopewell Therapeutics
Limax Biosciences
MediSix Therapeutics
NanoView Biosciences
NextGen Jane
PanTher Therapeutics
Quaise Energy
Stemloop
Suono Bio
Syntis Bio
Teal Bio
Verseau Therapeutics
Josh helps entrepreneurs build their businesses and advises them on significant transactions in the life cycle of their companies, with a particular focus on fundraising transactions and exit events.
He represents founders, start-ups, and emerging companies, serving as general counsel to those start-ups and emerging companies. Josh advises clients regarding company formation and early-stage legal issues, a broad range of financings, including angel, venture capital, and strategic investments, and mergers and acquisitions. He also provides guidance on legal and business matters that arise in the daily operations of their businesses.
Josh typically works with companies in the life sciences industry — drug development, devices, diagnostics, and tools — and in the technology sector, including energy, digital health, software, and technology-enabled services.
In addition to counseling entrepreneurs and emerging companies, Josh represents venture capital firms, foundations, and other investors.
Josh frequently speaks about topics related to entrepreneurship, financing, exit strategies, and best practices for businesses. He has also been a lecturer at the Boston University School of Law, teaching a class on venture capital financings that he created.
Josh maintains an active pro bono practice and is involved in the firm’s operations, including hiring activities.
Professional details:
Member, Mintz Venture Capital & Emerging Companies, Mergers & Acquisitions, Securities & Capital Markets, Mintz Hiring Committee (Corporate Section)
Chambers USA: Nationwide - Start Ups and Emerging Companies (2023)
Boston Magazine Top Lawyers – Corporate Law (2021)
Legal 500 United States for Finance: Capital Markets – Equity Offerings: Advice to Managers (2016)
Boston Magazine New England Super Lawyers Rising Stars (2008, 2010-2016)
Lecturer, Boston University School of Law
Board of Directors, Lawyers for Civil Rights
Education
JD, Harvard Law School
BA, summa cum laude, Tufts University
Josh’s Latest Thoughts
As VC deals shrink, convertible fundraisings are on the rise
Venture-backed valuations were down more than 15% at every stage of the startup lifecycle over the past year. At Series B and beyond, they’re down more than 40%. For many startups seeking new capital, this shift in the VC environment creates an unappealing possibility: having to raise a down round.
Biotech Startups, VCs Seek Path Forward After A Bruising Year
Mintz Member Joshua Fox spoke to the Wall Street Journal about what's ahead for biotech startups and venture capitalists following a difficult year. Joshua said, "Entrepreneurs seeking to start biotechs worry they won’t be able to attract sufficient capital, while some of those seeking new venture rounds fear they will be unable to raise enough to reach the next significant milestone before their cash runs out. Time is of the essence."
Inside The Secretive World Of Shark Tank Deals: Who The Real Winners Are
Mintz Member Joshua Fox spoke to Forbes about the logistics of Shark Tank and how deal terms develop after filming. Josh explained that small business owners are more vulnerable to onerous terms because they lack the same plethora of options for financing as larger business. He continued and shared, "If the entrepreneur can get several different investors to propose terms for an investment, the entrepreneur is going to be in a better position in its ability to resist the protections that certain investors may request."